{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:47:13Z","timestamp":1771976833878,"version":"3.50.1"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T00:00:00Z","timestamp":1393891200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0089789","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T22:47:58Z","timestamp":1393973278000},"page":"e89789","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and Safety of Tenofovir Disoproxil Fumarate in Asian-Americans with Chronic Hepatitis B in Community Settings"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00736190","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Calvin Q.","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huy","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sing","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Study 123 Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,3,4]]},"reference":[{"key":"ref1","first-page":"507","article-title":"Eliminating the threat of chronic hepatitis B in the Asian and Pacific Islander community: a call to action","volume":"10","author":"SD Chao","year":"2009","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref2","first-page":"505","article-title":"Screening for chronic hepatitis B among Asian\/Pacific Islander populations\u2013New York City, 2005","volume":"55","author":"H Pollack","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/07448481.2010.486811","article-title":"Prevalence of hepatitis B surface antigen in US-born and foreign-born Asian\/Pacific Islander college students","volume":"59","author":"YN Quang","year":"2011","journal-title":"J Am Coll Health"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.21784","article-title":"Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California","volume":"46","author":"SY Lin","year":"2007","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4254\/wjh.v3.i2.31","article-title":"Hepatitis B prevention and control: Lessons from the East and the West","volume":"3","author":"MC Robotin","year":"2011","journal-title":"World J Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.amjmed.2008.03.005","article-title":"Racial and ethnic variations in hepatocellular carcinoma incidence within the United States","volume":"121","author":"R Wong","year":"2008","journal-title":"Am J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"AS Lok","year":"2007","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"J Hepatol","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/135965350601100614","article-title":"Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy","volume":"11","author":"YF Liaw","year":"2006","journal-title":"Antivir Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"T Hosaka","year":"2013","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.25937","article-title":"Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy","volume":"57","author":"CL Lai","year":"2013","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"AS Lok","year":"2009","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1007\/s10620-011-1841-5","article-title":"The management of chronic hepatitis B in Asian Americans","volume":"56","author":"MJ Tong","year":"2011","journal-title":"Dig Dis Sci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"P Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"381","author":"P Marcellin","year":"2013","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/j.gastro.2010.06.053","article-title":"Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection","volume":"139","author":"T Berg","year":"2010","journal-title":"Gastroenterology"},{"key":"ref17","first-page":"200A","article-title":"Efficacy and safety of tenofovir DF in chronic hepatitis B virus infected patients with documented lamivudine resistance","volume":"56(Suppl)S14","author":"S Fung","year":"2012","journal-title":"Hepatology"},{"key":"ref18","first-page":"389A","article-title":"Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-na\u00efve patients with chronic hepatitis B followed for 3 years in a multicenter European study","volume":"56","author":"P Lampertico","year":"2012","journal-title":"Hepatology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1016\/S0168-8278(12)60543-1","article-title":"High efficacy and safety of tenofovir DF in 441 na\u00efve and NUC-experienced chronic hepatitis B patients: a real life multicentre prospective cohort study","volume":"56","author":"P Marcellin","year":"2012","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1016\/S0168-8278(12)60550-9","article-title":"Tenofovir DF for chronic hepatitis B patients in field practice \u2013 results from the GEMINIS German multicenter observational study","volume":"56","author":"J Petersen","year":"2012","journal-title":"J Hepatol"},{"issue":"suppl 2","key":"ref21","first-page":"S544","article-title":"A European field study of the efficacy and safety of tenofovir disoproxil fumerate (TDF) monotherapy in patients with prior failure to other nucleoside\/nucleotide analogues","volume":"57","author":"F van Bommel","year":"2012","journal-title":"J Hepatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3851\/IMP2481","article-title":"Long-term therapy with nucleoside\/nucleotide analogues for chronic hepatitis B in Asian patients","volume":"18","author":"CQ Pan","year":"2013","journal-title":"Antivir Ther"},{"issue":"Suppl 1","key":"ref23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1440-1746.2010.06541.x","article-title":"The clinical implications of hepatitis B virus genotype: Recent advances","volume":"26","author":"CL Lin","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-230X-7-40","article-title":"Meta-analyses of FibroTest diagnostic value in chronic liver disease","volume":"7","author":"T Poynard","year":"2007","journal-title":"BMC Gastroenterol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jhep.2012.04.025","article-title":"Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population","volume":"57","author":"T Poynard","year":"2012","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.24078","article-title":"No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus","volume":"53","author":"A Snow-Lampart","year":"2011","journal-title":"Hepatology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2036.2010.04555.x","article-title":"Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy","volume":"33","author":"V Rijckborst","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/hep.1840360617","article-title":"Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection","volume":"36","author":"CJ Chu","year":"2002","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/jmv.23371","article-title":"Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance","volume":"84","author":"F Ikeda","year":"2012","journal-title":"J Med Virol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1086\/656528","article-title":"Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections","volume":"202","author":"RM Ribeiro","year":"2010","journal-title":"J Infect Dis"},{"issue":"Suppl S1","key":"ref31","first-page":"746A","article-title":"Tenofovir disoproxil fumarate (TDF) versus adefovir dipivoxil (ADV) in Asians with HBeAg-positive and HBeAg-negative chronic hepatitis B participating I studies 102 and 103","volume":"48","author":"SS Lee","year":"2008","journal-title":"Hepatology"},{"key":"ref32","first-page":"1038A","article-title":"Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B infection in Asian patients is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis","volume":"54","author":"EJ Gane","year":"2011","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2893.2009.01146.x","article-title":"Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-na\u00efve HBeAg-positive patients with chronic hepatitis B","volume":"17","author":"RG Gish","year":"2010","journal-title":"J Viral Hepat"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jhep.2011.09.024","article-title":"Clinical evidence for the regression of liver fibrosis","volume":"56","author":"EL Ellis","year":"2012","journal-title":"J Hepatol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrgastro.2013.13","article-title":"Hepatitis: Long-term therapy of chronic hepatitis B reverses cirrhosis","volume":"10","author":"AS Lok","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-230X-11-91","article-title":"Non-invasive markers for hepatic fibrosis","volume":"11","author":"A Baranova","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0399-8320(08)73991-5","article-title":"FibroTest-ActiTest as a non-invasive marker of liver fibrosis","volume":"32","author":"P Halfon","year":"2008","journal-title":"Gastroenterol Clin Biol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e35825","DOI":"10.1371\/journal.pone.0035825","article-title":"Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B","volume":"7","author":"BK Kim","year":"2012","journal-title":"PLoS One"},{"key":"ref39","first-page":"382A","article-title":"No detectable resistance to Tenofovir Disoproxil Fumarate (TDF) or TDF plus Emtricitabine (FTC\/TDF) combination therapy through 96 Weeks in chronic hepatitis B (CHB) patients with documented resistance to lamivudine (LAM)","volume":"56","author":"AC Corsa","year":"2012","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0098723","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,5,23]],"date-time":"2014-05-23T00:00:00Z","timestamp":1400803200000}}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0089789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T22:59:45Z","timestamp":1689029985000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0089789"}},"subtitle":[],"editor":[{"given":"Vincent","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,4]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0089789","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0098723","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,4]]}}}